Evidence map›Paper›PMID 34537770›Full record

ReviewDermatology (Basel, Switzerland)2022

International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting.

Alison H Kohn, Afsaneh Alavi, April W Armstrong, Folawiyo Babalola, Amit Garg, Alice B Gottlieb, Lesley Grilli, Gregor Borut Ernst Jemec, John Latella, Kendall Marcus and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Article
  4. Approach to the Atypical Wound.American journal of clinical dermatology · 2024
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alison H KohnCharles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA.
Afsaneh AlaviDivision of Dermatology, University of Toronto, Toronto, Ontario, Canada.
April W ArmstrongDepartment of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, armstrongpublication@gmail.com.
Folawiyo BabalolaJoe R. & Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Amit GargDepartment of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA.
Alice B GottliebDepartment of Dermatology, Icahn School of Medicine at Mt Sinai, New York, New York, USA.
Lesley GrilliPatient Research Partner, International Dermatology Outcome Measures (IDEOM), Cohasset, Massachusetts, USA.
Gregor Borut Ernst JemecDepartment of Dermatology, Zealand University Hospital, Roskilde, Denmark.
John LatellaPatient Research Partner, International Dermatology Outcome Measures (IDEOM), Windsor, Connecticut, USA.
Kendall MarcusDivision of Dermatology and Dental Products, Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA.
Joseph F MerolaDepartment of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Alex G Ortega-LoayzaDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
Daniel M SiegelDepartment of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA.
Vibeke StrandDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
Jerry K L TanFaculty of Medicine, Western University, London, Ontario, Canada.
Lourdes M Perez-ChadaDepartment of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. SUMMARY: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. KEY MESSAGES: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

Indexed as

Acne VulgarisArthritis, PsoriaticDermatologyHidradenitis SuppurativaKeratosis, ActinicPsoriasisPyoderma GangrenosumHumansOutcome Assessment, Health CareAcneActinic keratosisHidradenitis suppurativaIDEOMPatient-Reported Outcome MeasuresPsoriasisPsoriatic arthritisPyoderma gangrenosum

Identifiers

PMID34537770
PMCPMC9153366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.